Analysts at Leerink Partners said in a Monday note that DESTIN-Breast09’s findings “could support an approval” for Enhertu in ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the DESTINY-Breast09 Phase 3 trial of Enhertu (5.4mg/kg) ...

The trial aims to assess the safety and efficacy of Enhertu, either as a single agent or with pertuzumab, against the THP.

A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer has interim clinical data showing it helped patients ...

AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the ...

AstraZeneca (LSE:AZN) recently reported a 1.9% decline in its share price over the last week. This movement coincides with ...

The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...

(RTTNews) - Daiichi Sankyo Co., Ltd. (DSKYF.PK ... AZN), Plus Pertuzumab showed positive topline results in a phase 3 trial in breast cancer patients. The results from a planned interim analysis ...

Daiichi Sankyo seeks Japanese approval for Enhertu to treat patients with HER2 positive metastatic solid tumours: Tokyo Friday, April 25, 2025, 09:00 Hrs [IST] Daiichi Sankyo has ...

Negative Breast Cancer Market Insight, Epidemiology and Market Forecast - 2035" report delivers comprehensive insights into triple-negative breast cancer, i ...